Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Net Cash Flow (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Net Cash Flow for 4 consecutive years, with $6.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Cash Flow rose 15450.34% to $6.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.9 million, a 284.21% increase, with the full-year FY2024 number at -$1.7 million, up 80.03% from a year prior.
  • Net Cash Flow was $6.9 million for Q3 2025 at bioAffinity Technologies, up from $358129.0 in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $13.3 million in Q3 2022 to a low of -$3.8 million in Q3 2023.
  • A 4-year average of $435236.3 and a median of -$660585.0 in 2025 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: plummeted 394.48% in 2023, then soared 15450.34% in 2025.
  • bioAffinity Technologies' Net Cash Flow stood at -$1.9 million in 2022, then grew by 9.47% to -$1.7 million in 2023, then skyrocketed by 120.66% to $348711.0 in 2024, then soared by 1869.07% to $6.9 million in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Net Cash Flow are $6.9 million (Q3 2025), $358129.0 (Q2 2025), and -$660585.0 (Q1 2025).